Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer

The European Medicines Agency's CHMP has recommended approval of Roche's Itovebi in combination with Pfizer's Ibrance and AstraZeneca's Faslodex for PIK3CA-mutated, ER-positive, HER2-negative, locally advanced or metastatic breast cancer in the EU, mirroring its existing approval in the United States. The recommendation is based on the INAVO120 study, which demonstrated a 57% reduction in disease progression or death compared to Ibrance and Faslodex alone, with a statistically significant survival advantage also observed. This approval could redefine the standard of care for first-line treatment of this aggressive form of breast cancer.

Analysis

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending EU approval for Roche's Itovebi (inavolisib) as a combination therapy with Pfizer's Ibrance and AstraZeneca's Faslodex. This recommendation targets adult patients with PIK3CA-mutated, ER-positive, HER2-negative, locally advanced or metastatic breast cancer who experienced recurrence on or within 12 months of completing adjuvant endocrine treatment. The CHMP's stance is underpinned by the phase III INAVO120 study, which demonstrated a significant 57% reduction in the risk of disease progression or death for the Itovebi-based regimen compared to Ibrance and Faslodex alone in the first-line setting; this benefit was consistent across all pre-specified subgroups and the regimen was well tolerated. According to the article, positive top-line results from the final overall survival (OS) analysis of the INAVO120 study, announced in January 2025, confirmed a statistically significant and clinically meaningful survival advantage, with full OS results slated for presentation at the 2025 American Society of Clinical Oncology Annual Meeting. Given that PIK3CA mutations, present in approximately 40% of HR-positive breast cancers, are associated with more aggressive disease and poorer outcomes, the Itovebi-based regimen, which is already approved in the United States and other geographies for the same indication, has the potential to redefine the standard of care in this first-line setting where treatment options are limited. Roche's stock (RHHBY) performance, with a 13.7% year-to-date surge against the industry's 5.7% decline, reflects positive investor sentiment, further supported by Roche's ongoing evaluation of Itovebi in other late-stage studies and plans for broader clinical investigations.

Key Decisions for Investors

• The positive CHMP opinion for Itovebi significantly de-risks its path to market in the European Union, a key commercial territory for Roche, and supports potential revenue growth within its oncology franchise.
• Investors should closely monitor the final European Commission decision, expected soon, and the comprehensive overall survival data presentation at the 2025 ASCO meeting, as these events will be critical in assessing the drug's full clinical and commercial potential.
• Given Itovebi's strong efficacy data, existing approvals in other major markets, and Roche's outperforming stock, this regulatory milestone reinforces the value of Roche's pipeline and its competitive positioning in treating PIK3CA-mutated breast cancer.